Synopsis
Synopsis
0
USDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 21-chloro-11-dehydro-betamethasone-17-butyrate
2. Clobetasone 17-butyrate
3. Emovate
4. Eumovate
5. Trimovate
1. 25122-57-0
2. Clobetasone 17-butyrate
3. Cci 5537
4. Kindavate
5. Gr 2/1214
6. 8u0h6xi6eo
7. 21-chloro-9-fluoro-17-hydroxy-16-methylpregna-1,4-diene-3,11,20-trione 17-butyrate
8. 21-chloro-9-fluoro-17-hydroxy-16beta-methylpregna-1,4-diene-3,11,20-trione 17-butyrate
9. Gnf-pf-1500
10. Mls000028658
11. Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16beta)-
12. Emovate
13. Molivate
14. Smr000058879
15. Dsstox_cid_26823
16. Dsstox_rid_81935
17. Dsstox_gsid_46823
18. [(8s,9r,10s,13s,14s,16s,17r)-17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] Butanoate
19. Cloptison
20. Cas-25122-57-0
21. Clobetasone Butyrate [usan:jan]
22. Einecs 246-635-9
23. Sn 203
24. Unii-8u0h6xi6eo
25. Cci-5537
26. Clofasone Butyrate
27. Kindavate (tn)
28. Ncgc00181043-01
29. Clobetasone-butyrate
30. Mfcd00133196
31. Butyric Acid Clobetasone
32. Opera_id_1547
33. 21-chloro-9-fluoro-17-hydroxy-16-beta-methylpregna-1,4-diene,3,11,20-trione Butyrate
34. 21-chloro-9-fluoro-17-hydroxy-16beta-methylpregna-1,4-diene-3,11,20-trione Butyrate
35. Schembl36599
36. Mls001076290
37. Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16-beta)-
38. Clobetasone Butyrate, >=98%
39. Chembl577673
40. Dtxsid3046823
41. Chebi:31415
42. Clobetasone Butyrate (jan/usan)
43. Clobetasone Butyrate [jan]
44. Hms2234b13
45. Clobetasone Butyrate [usan]
46. Hy-b1616
47. Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16.beta.)-
48. Zinc4215391
49. Tox21_112691
50. Clobetasone Butyrate [mart.]
51. S6587
52. Clobetasone Butyrate [who-dd]
53. Akos037748814
54. Clobetasone 17-butyrate [mi]
55. Tox21_112691_1
56. Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-17-hydroxy-16-beta-methyl-, Butyrate
57. Ncgc00022019-03
58. As-14689
59. Clobetasone Butyrate [ep Monograph]
60. Clobetasone Butyrate For System Suitability
61. Gr-2/1214
62. C3510
63. Cs-0013549
64. D01273
65. T70655
66. 122c570
67. A924946
68. Sr-01000000249
69. Clobetasone Butyrate 100 Microg/ml In Acetonitrile
70. Sr-01000000249-3
71. W-107264
72. Q27271005
73. Clobetasone Butyrate, European Pharmacopoeia (ep) Reference Standard
74. (16beta)-21-chloro-9-fluoro-16-methyl-3,11,20-trioxopregna-1,4-dien-17-yl Butyrate
75. Clobetasone Butyrate For System Suitability, European Pharmacopoeia (ep) Reference Standard
76. 21-chloro-9-fluoro-17-hydroxy-16.beta.-methylpregna-1,4-diene-3,11,20-trione Butyrate
77. Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16b)-
Molecular Weight | 479.0 g/mol |
---|---|
Molecular Formula | C26H32ClFO5 |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 478.1922300 g/mol |
Monoisotopic Mass | 478.1922300 g/mol |
Topological Polar Surface Area | 77.5 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 987 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
Certificate Number : R1-CEP 2012-282 - Rev 00
Issue Date : 2019-10-17
Type : Chemical
Substance Number : 1090
Status : Valid
Registration Number : 229MF10100
Registrant's Address : 385/2, Pigdamber, Off. A. B. Road, Rau, Indore 453331 (M.P.) India
Initial Date of Registration : 2017-06-02
Latest Date of Registration : --
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Certificate Number : CEP 2018-105 - Rev 01
Issue Date : 2024-10-29
Type : Chemical
Substance Number : 1090
Status : Valid
Registration Number : 219MF10361
Registrant's Address : Via San Vittore, 39-20123 Milano (Italy)
Initial Date of Registration : 2007-12-13
Latest Date of Registration : --
Certificate Number : R1-CEP 2006-186 - Rev 02
Issue Date : 2013-08-06
Type : Chemical
Substance Number : 1090
Status : Withdrawn by Holder
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Dosage Form :
Dosage Strength : Coll 5 Ml 1 Mg/Ml
Price Per Pack (Euro) : 3.25
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Dosage Form : Cream
Dosage Strength :
Price Per Pack (Euro) : 3.46
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
VISUFARMA SpA
Dosage Form :
Dosage Strength : Coll 10 Ml 1 Mg/Ml
Price Per Pack (Euro) : 9.08
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
12 Jan 2023
Reply
12 Apr 2022
Reply
29 Mar 2021
Reply
19 Dec 2019
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Clobetasone Butyrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clobetasone Butyrate, including repackagers and relabelers. The FDA regulates Clobetasone Butyrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clobetasone Butyrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clobetasone Butyrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clobetasone Butyrate supplier is an individual or a company that provides Clobetasone Butyrate active pharmaceutical ingredient (API) or Clobetasone Butyrate finished formulations upon request. The Clobetasone Butyrate suppliers may include Clobetasone Butyrate API manufacturers, exporters, distributors and traders.
click here to find a list of Clobetasone Butyrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Clobetasone Butyrate Drug Master File in Japan (Clobetasone Butyrate JDMF) empowers Clobetasone Butyrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Clobetasone Butyrate JDMF during the approval evaluation for pharmaceutical products. At the time of Clobetasone Butyrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Clobetasone Butyrate suppliers with JDMF on PharmaCompass.
A Clobetasone Butyrate CEP of the European Pharmacopoeia monograph is often referred to as a Clobetasone Butyrate Certificate of Suitability (COS). The purpose of a Clobetasone Butyrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clobetasone Butyrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clobetasone Butyrate to their clients by showing that a Clobetasone Butyrate CEP has been issued for it. The manufacturer submits a Clobetasone Butyrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clobetasone Butyrate CEP holder for the record. Additionally, the data presented in the Clobetasone Butyrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clobetasone Butyrate DMF.
A Clobetasone Butyrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clobetasone Butyrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Clobetasone Butyrate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Clobetasone Butyrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Clobetasone Butyrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Clobetasone Butyrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Clobetasone Butyrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Clobetasone Butyrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Clobetasone Butyrate suppliers with NDC on PharmaCompass.
Clobetasone Butyrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clobetasone Butyrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clobetasone Butyrate GMP manufacturer or Clobetasone Butyrate GMP API supplier for your needs.
A Clobetasone Butyrate CoA (Certificate of Analysis) is a formal document that attests to Clobetasone Butyrate's compliance with Clobetasone Butyrate specifications and serves as a tool for batch-level quality control.
Clobetasone Butyrate CoA mostly includes findings from lab analyses of a specific batch. For each Clobetasone Butyrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clobetasone Butyrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Clobetasone Butyrate EP), Clobetasone Butyrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clobetasone Butyrate USP).
LOOKING FOR A SUPPLIER?